Dr. Alexander Spira, MD
Claim this profileVirginia Cancer Specialists
Expert in Lung Cancer
Expert in Solid Tumors
139 reported clinical trials
181 drugs studied
About Alexander Spira, MD
Education:
- Earned an MD from New York University School of Medicine.
- Received a PhD from the New York School of Arts and Sciences.
Experience:
- Completed an internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania.
- Undertook a medical oncology fellowship at Johns Hopkins Hospital.
- Serves as Director of the Virginia Cancer Specialists Research Institute and the Phase I Trial Program.
- Holds positions as Clinical Assistant Professor and Assistant Professor of Oncology at Johns Hopkins School of Medicine.
- Actively involved in leadership roles within the USOncology network, including Co-Chair of the Thoracic Oncology Committee.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Solid Tumors
Global LeaderStage IV
Stage III
KRAS positive
Affiliated Hospitals
Clinical Trials Alexander Spira, MD is currently running
M9140
for Solid Tumors
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).
Recruiting1 award Phase 1 & 29 criteria
TNG462
for Solid Cancers
This trial is testing a new oral drug called TNG462 in patients with advanced or metastatic solid tumors that have an MTAP deletion. The drug works by blocking a protein that helps these cancer cells grow. The goal is to see if TNG462 can stop the cancer from growing and spreading.
Recruiting1 award Phase 1 & 2
More about Alexander Spira, MD
Clinical Trial Related4 years of experience running clinical trials · Led 139 trials as a Principal Investigator · 55 Active Clinical TrialsTreatments Alexander Spira, MD has experience with
- Pembrolizumab
- Nivolumab
- Docetaxel
- Avutometinib (VS-6766)
- Gemcitabine
- Placebo
Breakdown of trials Alexander Spira, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander Spira, MD specialize in?
Alexander Spira, MD focuses on Lung Cancer and Solid Tumors. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Alexander Spira, MD currently recruiting for clinical trials?
Yes, Alexander Spira, MD is currently recruiting for 54 clinical trials in Fairfax Virginia. If you're interested in participating, you should apply.
Are there any treatments that Alexander Spira, MD has studied deeply?
Yes, Alexander Spira, MD has studied treatments such as Pembrolizumab, Nivolumab, Docetaxel.
What is the best way to schedule an appointment with Alexander Spira, MD?
Apply for one of the trials that Alexander Spira, MD is conducting.
What is the office address of Alexander Spira, MD?
The office of Alexander Spira, MD is located at: Virginia Cancer Specialists, Fairfax, Virginia 22031 United States. This is the address for their practice at the Virginia Cancer Specialists.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.